**Author details**

Daniel Simplicio Torres1 \*, Jefferson Abrantes2 \* and Carlos Eduardo Brandão-Mello2 \*

1 Rio de Janeiro State University (UERJ), RJ, Brazil

2 Federal University of the State of Rio de Janeiro (UNIRIO), RJ, Brazil

\*Address all correspondence to: daniel.simplicio@hotmail.com, jeffabrantes@uol. com.br and cedubrandao@gmail.com

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**55**

*The Neurobiology of Hepatic Encephalopathy DOI: http://dx.doi.org/10.5772/intechopen.86320*

[1] Osler W. The Evolution of Modern Medicine. Fairford: Echo Library; 2009. axis. Metabolic Brain Disease.

[10] Butterworth RF. Pathogenesis of hepatic encephalopathy in cirrhosis: The concept of synergism revisited. Metabolic Brain Disease.

[11] Su YY, Yang GF, Lu GM, WU S, Zhang LJ. PET and MRI imaging of neuroinflammation in hepatic encephalopathy. Metabolic Brain Disease. 2015;**30**(1):31-45

[12] Oja SS, Saransaari P, Korpi ER. Neurotoxicity of ammonia.

[13] Baker L, Lanz B, Andreola F, Apuero J, Wijeyesekera A, Holmes E, et al. New technologies—New insights into the pathogenesis of hepatic encephalopathy. Metabolic Brain Disease. 2016;**31**(6):1259-1267

[14] Ahluwalia V, Betrapally NS, Hylemon PB, White MB, Gillevet PM, Unser AB, et al. Impaired gut-liverbrain axis in patients with cirrhosis. Scientific Reports. 2016;**6**:26800

[15] Milewski K, Oriua M. What we know: The inflammatory basis of hepatic encephalopathy. Metabolic Brain

Disease. 2016;**31**(6):1239-1247

(part III): Non-absorbable

2016;**31**(6):1361-1364

[16] Morgan MY. Current state of knowledge of hepatic encephalopathy

[17] Merli M, Iebba V, Giusto M. What is new about diet in hepatic encephalopathy. Metabolic Brain Disease. 2016;**31**(6):1289-1294

dissacharides. Metabolic Brain Disease.

[18] Dabos KJ, Parkinson JA, Sadler IH, Plevris JN, Hayes PC. 1H nuclear

Neurochemical Research. 2017;**42**(3):

2016;**31**(6):1327-1337

2016;**31**(6):1211-1215

713-720

[2] Dooley JS, Lok A, Burroughs AK, Heathcote J. Sherlock's Diseases of the Liver and Biliary Systems. 12th ed. West

[3] Fuentes F, Malloy-Diniz LF, Ciancio A, Sacco A. Neuropsicologia: Teoria e Prática. 2nd ed. Porto Alegre: Artmed; 2014

Sussex: Wiley-Blackwell; 2011

[4] Montana V, Verhrastsky A, Parpura V. Pathological role for exocytotic glutamate release from astrocytes in hepatic encephalopathy.

Current Neuropharmacology.

[6] Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;**60**(2):715-735

[7] Torres DS, Abrantes J, Brandão-Mello CE. Cognitive assessment of patients with minimal hepatic encephalopathy in Brazil. Metabolic Brain Disease.

[8] Morgan MY, Amodio P, Cook NA, Jackson CD, Kircheis G, Lauridsen MM, et al. Qualifying and quantifying minimal hepatic encephalopathy.

[9] Patel VC, White H, Stoy S, Bajaj JS, Shawcross DL. Clinical science

workshop: Targeting the gut-liver-bain

[5] Amodio P, Montagnese S, Mullen K, Orr JG, Vilstrup H. Where are we going? Translational research in hepatic encephalopathy. Metabolic Brain Disease. 2016;**31**(6):1231-1237

2014;**12**(4):324-333

2013;**28**(3):473-483

Metabolic Brain Disease. 2016;**31**(6):1217-1229

**References**

pp. 20-26

*The Neurobiology of Hepatic Encephalopathy DOI: http://dx.doi.org/10.5772/intechopen.86320*
